CARMEL, Ind., May 28, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it has been awarded a contract by the Health Care Authority (HCA) in Washington State to provide essential behavioral health and recovery training and support services. This marks an important milestone as Washington becomes the 20th state where Syra Health has established, active contracts.
Under the terms of the agreement, Syra Health will be providing behavioral health and recovery training and support services to help strengthen the recruitment and retention of a qualified behavioral health workforce in Washington State.
To address this need, Syra Health will deliver comprehensive training across seven key categories:
The training programs are designed to equip behavioral health professionals with the latest knowledge and skills necessary to effectively address and manage various mental health and substance use disorders. These initiatives will play a pivotal role in enhancing service delivery across multiple care settings, ensuring a holistic approach to behavioral health care. By focusing on both prevention and treatment, the programs aim to reduce the overall burden of mental health issues and substance use disorders in Washington State.
"Winning this contract in Washington State marks a significant step forward for Syra Health as we continue our rapid expansion across the country," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "We currently provide similar trainings in Arizona, Indiana, and Kansas. Improving mental and behavioral health care is one of our corporate goals. A key piece of achieving this goal is improving the quality of behavioral health care by equipping providers with the needed training and support."
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.
FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.37 |
Daily Change: | -0.01 -3.46 |
Daily Volume: | 91,347 |
Market Cap: | US$3.300M |
October 29, 2024 September 13, 2024 August 08, 2024 July 30, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB